| Citation: |
DONG Ying, ZHANG Xiong, YANG Wei, LI Zan, LE Ying, GU Maoqun. Therapeutic effect of allogeneic hematopoietic stem cell transplantation on acute myeloid leukemia and influencing factors of survival prognosis[J]. Journal of Clinical Medicine in Practice, 2024, 28(22): 41-45. DOI: 10.7619/jcmp.20241705
|
To observe the therapeutic effect of allogeneic hematopoietic stem cell transplantation (allo-HSCT) on acute myeloid leukemia (AML) and analyze the influencing factors of survival prognosis.
The clinical data of 32 AML patients who underwent allo-HSCT treatment were retrospectively analyzed. The hematopoietic reconstitution, occurrence of graft-versus-host disease (GVHD), survival status, recurrence, and transplantation-related mortality (TRM) of patients were observed, and the influencing factors of survival prognosis were analyzed.
All 32 AML patients who underwent allo-HSCT achieved granulocyte reconstitution, with a time range of 10 to 26 days and a median time of 11.0 days. Granulocyte-macrophage lineage reconstitution was achieved in 30 patients, with a time range of 10 to 54 days and a median time of 13.5 days. Among the 30 evaluable patients, 10 developed acute GVHD (with incidence rate of 33.33%) and 10 developed chronic GVHD (incidence rate of 33.33%). Up to May 31, 2023, the follow-up time ranged from 2 to 28 months, with a median follow-up time of 14.5 months. Of the 30 patients, 28 survived (25 patients were in disease-free survival status), and 2 died. Multivariate Cox regression analysis showed that age>35 years (P=0.035, HR=2.021) and recurrence after transplantation (P=0.021, HR=2.546) were independent risk factors of patients' survival prognosis. Among 30 patients, 5 relapsed, with a time range of 6 to 24 months and a median time of 9.0 months. Of 5 relapsed patients, 2 died (non-TRM).
Allo-HSCT is an effective treatment for AML. Age>35 years and recurrence after transplantation are independent risk factors of patients' survival prognosis.
| [1] |
黄可秀, 王云鲭, 李迪, 等. 真实世界遗传学高危的急性髓系白血病患者临床结局分析[J]. 中国肿瘤临床, 2023, 50(3): 150-156.
|
| [2] |
王卫东, 王绮昀, 艾丽丝, 等. 急性髓系白血病发生机制研究进展[J]. 中国细胞生物学学报, 2021, 43(7): 1523-1535.
|
| [3] |
朱原辛, 贾韬, 毛建平, 等. G-CSF联合GM-CSF及高剂量G-CSF治疗急性髓系白血病化疗后中性粒细胞缺乏的疗效观察[J]. 现代肿瘤医学, 2023, 31(3): 503-506. doi: 10.3969/j.issn.1672-4992.2023.03.022
|
| [4] |
李文凤, 周靖博, 赵艳红, 等. 复发难治性急性髓系白血病治疗现状及新药进展[J]. 中国实验血液学杂志, 2022, 30(6): 1907-1911.
|
| [5] |
张荣莉, 姜尔烈. 新型靶向药吉瑞替尼在伴FLT3突变急性髓系白血病治疗的临床应用进展[J]. 白血病·淋巴瘤, 2023, 32(6): 377-381. doi: 10.3760/cma.j.cn115356-20220916-00261
|
| [6] |
马薇, 张改玲, 张薇, 等. 异基因造血干细胞移植对第一次形态学完全缓解急性髓系白血病患者预后的影响研究[J]. 湖南师范大学学报: 医学版, 2021, 18(2): 209-213. doi: 10.3969/j.issn.1673-016X.2021.02.060
|
| [7] |
DUVAL M, KLEIN J P, HE W S, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure[J]. J Clin Oncol, 2010, 28(23): 3730-3738. doi: 10.1200/JCO.2010.28.8852
|
| [8] |
冯丹, 王铭洋, 刘佳, 等. 异基因造血干细胞移植治疗伴TP53基因异常骨髓增生异常综合征/急性髓系白血病42例疗效分析[J]. 中华血液学杂志, 2023, 44(3): 222-229.
|
| [9] |
中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅰ): 适应证、预处理方案及供者选择(2014年版)[J]. 中华血液学杂志, 2014, 35(8): 775-780.
|
| [10] |
中华医学会血液学分会白血病淋巴瘤学组. 成人急性髓系白血病(非急性早幼粒细胞白血病)中国诊疗指南(2017年版)[J]. 中华血液学杂志, 2017, 38(3): 177-182.
|
| [11] |
中华医学会血液学分会白血病淋巴瘤学组. 复发难治性急性髓系白血病中国诊疗指南(2017年版)[J]. 中华血液学杂志, 2017, 38(3): 183-184.
|
| [12] |
宋慧慧, 李明春. 急性髓系白血病基因水平发病机制的研究进展[J]. 中国现代应用药学, 2020, 37(3): 371-377.
|
| [13] |
令狐顺, 肖青, 王欣, 等. 老年急性髓系白血病患者临床特征与预后分析[J]. 中国药业, 2023, 32(12): 66-71. doi: 10.3969/j.issn.1006-4931.2023.12.016
|
| [14] |
梁春燕, 李增政, 王敏, 等. 细胞因子在急性髓系白血病预后中的研究进展[J]. 中国实验血液学杂志, 2022, 30(6): 1922-1926.
|
| [15] |
中华医学会血液学分会干细胞应用学组. 中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅲ): 急性移植物抗宿主病(2020年版)[J]. 中华血液学杂志, 2020, 41(7): 529-536.
|
| [16] |
徐诺, 陈香丽, 臧玉柱, 等. 异基因造血干细胞移植后发生移植物抗宿主病伴新的T细胞受体基因克隆性重排2例并文献复习[J]. 白血病·淋巴瘤, 2023, 32(6): 352-355. doi: 10.3760/cma.j.cn115356-20220914-00258
|
| [17] |
张文丽, 侯畅, 单蒙, 等. 异基因造血干细胞移植治疗老年人急性髓系白血病预后分析[J]. 白血病·淋巴瘤, 2020, 29(1): 30-36. doi: 10.3760/cma.j.issn.1009-9921.2020.01.007
|
| [18] |
马玲, 赵婷, 陈育红, 等. 继发性急性髓系白血病的治疗反应和结局及其影响因素分析[J]. 中华血液学杂志, 2023, 44(2): 124-131.
|
| [19] |
窦雪琳, 赵婷, 许兰平, 等. 成人初发急性髓系白血病患者年龄相关临床特征和预后[J]. 中华血液学杂志, 2018, 39(12): 969-976. doi: 10.3760/cma.j.issn.0253-2727.2018.12.001
|
| [20] |
夏晶, 赵晔, 陈峰, 等. 伴SET-NUP214融合基因急性白血病异基因造血干细胞移植疗效分析[J]. 中华内科杂志, 2023, 62(4): 410-415. doi: 10.3760/cma.j.cn112138-20220411-00264
|
| [21] |
李婷婷, 符粤文, 艾昊, 等. 复发难治急性髓系白血病异基因造血干细胞移植疗效及预后因素分析[J]. 白血病·淋巴瘤, 2020, 29(3): 146-152.
|
| [22] |
娄典, 刘利, 严学倩, 等. 异基因造血干细胞移植治疗难治/复发急性髓系白血病的疗效及预后因素分析[J]. 中国实验血液学杂志, 2022, 30(5): 1577-1585.
|
© 2020 《实用临床医药杂志》编辑部
Address: 江苏省扬州市江阳中路136号，扬州大学江阳路北校区14号楼201室China Pos: 225009Tel: 0514-87978917、87978989、87978807
Supported by:
Beijing Renhe Information Technology Co., Ltd.
苏公网安备 32100302010246号
DownLoad: